How to buy BioCryst Pharmaceuticals stock | $14.7

BioCryst Pharmaceuticals Inc is a biotechnology business based in the US. BioCryst Pharmaceuticals shares (BCRX) are listed on the NASDAQ and all prices are listed in US Dollars. BioCryst Pharmaceuticals employs 246 staff and has a trailing 12-month revenue of around 0.00.

BioCryst Pharmaceuticals stock price (NASDAQ: BCRX)

Use our graph to track the performance of BCRX stocks over time.

BioCryst Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-10-23.

Latest market close	$14.70
52-week range	$3.57 - $18.48
50-day moving average	$14.80
200-day moving average	$14.76
Wall St. target price	$21.27
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.21

Buy BioCryst Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy BioCryst Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

BioCryst Pharmaceuticals price performance over time

Historical closes compared with the close of $14.7 from 2021-10-22

1 week (2021-10-14)	N/A
1 month (2021-09-24)	-1.47%
3 months (2021-07-23)	-14.83%
6 months (2021-04-23)	21.19%

1 year (2020-10-23)	296.23%
2 years (2019-10-24)	525.53%
3 years (2018-10-24)	125.81%
5 years (2016-10-24)	218.18%

BioCryst Pharmaceuticals financials

Revenue TTM	$79.1 million
Gross profit TTM	$-106,828,000
Return on assets TTM	-46.05%
Return on equity TTM	-1925.37%
Profit margin	-270.53%
Book value	$0.19
Market capitalisation	$2.6 billion

TTM: trailing 12 months

Shorting BioCryst Pharmaceuticals shares

There are currently 18.5 million BioCryst Pharmaceuticals shares held short by investors – that's known as BioCryst Pharmaceuticals's "short interest". This figure is 2.3% down from 19.0 million last month.

There are a few different ways that this level of interest in shorting BioCryst Pharmaceuticals shares can be evaluated.

BioCryst Pharmaceuticals's "short interest ratio" (SIR)

BioCryst Pharmaceuticals's "short interest ratio" (SIR) is the quantity of BioCryst Pharmaceuticals shares currently shorted divided by the average quantity of BioCryst Pharmaceuticals shares traded daily (recently around 2.3 million). BioCryst Pharmaceuticals's SIR currently stands at 8.21. In other words for every 100,000 BioCryst Pharmaceuticals shares traded daily on the market, roughly 8210 shares are currently held short.

However BioCryst Pharmaceuticals's short interest can also be evaluated against the total number of BioCryst Pharmaceuticals shares, or, against the total number of tradable BioCryst Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioCryst Pharmaceuticals's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 BioCryst Pharmaceuticals shares in existence, roughly 100 shares are currently held short) or 0.1165% of the tradable shares (for every 100,000 tradable BioCryst Pharmaceuticals shares, roughly 117 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against BioCryst Pharmaceuticals.

Find out more about how you can short BioCryst Pharmaceuticals stock.

BioCryst Pharmaceuticals share dividends

We're not expecting BioCryst Pharmaceuticals to pay a dividend over the next 12 months.

BioCryst Pharmaceuticals share price volatility

Over the last 12 months, BioCryst Pharmaceuticals's shares have ranged in value from as little as $3.57 up to $18.48. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioCryst Pharmaceuticals's is 2.5783. This would suggest that BioCryst Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.

BioCryst Pharmaceuticals overview

BioCryst Pharmaceuticals, Inc. , a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase I clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. BioCryst Pharmaceuticals, Inc. has collaborations and in-license relationships with the Torii Pharmaceutical Co. , Ltd.

Frequently asked questions

What percentage of BioCryst Pharmaceuticals is owned by insiders or institutions?
Currently 0.903% of BioCryst Pharmaceuticals shares are held by insiders and 59.505% by institutions. How many people work for BioCryst Pharmaceuticals?
Latest data suggests 246 work at BioCryst Pharmaceuticals. When does the fiscal year end for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals's fiscal year ends in December. Where is BioCryst Pharmaceuticals based?
BioCryst Pharmaceuticals's address is: 4505 Emperor Boulevard, Durham, NC, United States, 27703 What is BioCryst Pharmaceuticals's ISIN number?
BioCryst Pharmaceuticals's international securities identification number is: US09058V1035 What is BioCryst Pharmaceuticals's CUSIP number?
BioCryst Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 09058V103